BGCP - BGC Partners, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.5750
-0.0950 (-3.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.6700
Open2.6700
Bid2.5800 x 21500
Ask2.6400 x 28000
Day's Range2.5650 - 2.6750
52 Week Range2.0700 - 6.1500
Volume5,516,393
Avg. Volume4,708,450
Market Cap920.65M
Beta (5Y Monthly)2.19
PE Ratio (TTM)111.96
EPS (TTM)0.0230
Earnings DateJul 23, 2020 - Jul 27, 2020
Forward Dividend & Yield0.43 (16.10%)
Ex-Dividend DateMay 21, 2020
1y Target Est8.00
  • BGC Partners to Webcast Two Investor Events
    PR Newswire

    BGC Partners to Webcast Two Investor Events

    BGC Partners, Inc. (NASDAQ: BGCP) ("BGC Partners" or "BGC" or the "Company"), a leading global brokerage and financial technology company, today announced that its Chairman and CEO, Howard W. Lutnick, is scheduled to present at Piper Sandler's Global Exchange and Brokerage Conference at 1:30 p.m. ET on Wednesday, June 3, 2020. The Company also announced details on its annual meeting of stockholders, which will be held virtually at 10:00 am ET on Thursday, June 11, 2020.

  • Thomson Reuters StreetEvents

    Edited Transcript of BGCP earnings conference call or presentation 5-May-20 2:00pm GMT

    Q1 2020 BGC Partners Inc Earnings Call

  • Top Ranked Income Stocks to Buy for May 12th
    Zacks

    Top Ranked Income Stocks to Buy for May 12th

    Top Ranked Income Stocks to Buy for May 12th

  • Is BGC Partners (BGCP) Stock Undervalued Right Now?
    Zacks

    Is BGC Partners (BGCP) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Near-Term Outlook Bleak for Investment Banks on Coronavirus Scare
    Zacks

    Near-Term Outlook Bleak for Investment Banks on Coronavirus Scare

    Near-Term Outlook Bleak for Investment Banks on Coronavirus Scare

  • BGC Partners (BGCP) Q1 2020 Earnings Call Transcript
    Motley Fool

    BGC Partners (BGCP) Q1 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the BGC Partners, Inc. first-quarter earnings conference call. Good morning, and thank you all for joining us for our first-quarter 2020 conference call.

  • BGC Partners (BGCP) Meets Q1 Earnings Estimates
    Zacks

    BGC Partners (BGCP) Meets Q1 Earnings Estimates

    BGC Partners (BGCP) delivered earnings and revenue surprises of 0.00% and 1.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • BGC Partners Reports First Quarter 2020 Financial Results
    PR Newswire

    BGC Partners Reports First Quarter 2020 Financial Results

    BGC Partners, Inc. (NASDAQ: BGCP) ("BGC Partners," "BGC," or the "Company"), a leading global brokerage and financial technology company, today reported its financial results for the quarter ended March 31, 2020.

  • Top Ranked Income Stocks to Buy for May 1st
    Zacks

    Top Ranked Income Stocks to Buy for May 1st

    Top Ranked Income Stocks to Buy for May 1st

  • What Is BGC Partners's (NASDAQ:BGCP) P/E Ratio After Its Share Price Rocketed?
    Simply Wall St.

    What Is BGC Partners's (NASDAQ:BGCP) P/E Ratio After Its Share Price Rocketed?

    BGC Partners (NASDAQ:BGCP) shareholders are no doubt pleased to see that the share price has bounced 34% in the last...

  • BGC Partners (BGCP) Gains As Market Dips: What You Should Know
    Zacks

    BGC Partners (BGCP) Gains As Market Dips: What You Should Know

    In the latest trading session, BGC Partners (BGCP) closed at $3.10, marking a +0.16% move from the previous day.

  • Top Ranked Value Stocks to Buy for April 30th
    Zacks

    Top Ranked Value Stocks to Buy for April 30th

    Top Ranked Value Stocks to Buy for April 30th

  • BGC Partners (BGCP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks

    BGC Partners (BGCP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    BGC Partners (BGCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Top Ranked Value Stocks to Buy for April 28th
    Zacks

    Top Ranked Value Stocks to Buy for April 28th

    Top Ranked Value Stocks to Buy for April 28th

  • Is BGC Partners (BGCP) a Great Value Stock Right Now?
    Zacks

    Is BGC Partners (BGCP) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Top Ranked Value Stocks to Buy for April 24th
    Zacks

    Top Ranked Value Stocks to Buy for April 24th

    Top Ranked Value Stocks to Buy for April 24th

  • GAIN Capital (GCAP) Jumps: Stock Rises 7%
    Zacks

    GAIN Capital (GCAP) Jumps: Stock Rises 7%

    GAIN Capital (GCAP) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

  • BGC Partners (BGCP): The Perfect Mix of Value and Rising Earnings Estimates?
    Zacks

    BGC Partners (BGCP): The Perfect Mix of Value and Rising Earnings Estimates?

    BGC Partners (BGCP) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.

  • Top Ranked Value Stocks to Buy for April 22nd
    Zacks

    Top Ranked Value Stocks to Buy for April 22nd

    Top Ranked Value Stocks to Buy for April 22nd

  • Top Ranked Income Stocks to Buy for April 22nd
    Zacks

    Top Ranked Income Stocks to Buy for April 22nd

    Top Ranked Income Stocks to Buy for April 22nd

  • The Zacks Analyst Blog Highlights: Eloxx Pharmaceuticals, BGC Partners, SharpSpring, Ra Medical Systems and American States Water
    Zacks

    The Zacks Analyst Blog Highlights: Eloxx Pharmaceuticals, BGC Partners, SharpSpring, Ra Medical Systems and American States Water

    The Zacks Analyst Blog Highlights: Eloxx Pharmaceuticals, BGC Partners, SharpSpring, Ra Medical Systems and American States Water

  • BGC Partners' First Quarter 2020 Financial Results Announcement To Be Issued Prior To Market Open On Tuesday, May 5, 2020
    PR Newswire

    BGC Partners' First Quarter 2020 Financial Results Announcement To Be Issued Prior To Market Open On Tuesday, May 5, 2020

    BGC Partners, Inc. (NASDAQ: BGCP) ("BGC"), a leading global brokerage and financial technology company, today announced the details regarding its first quarter 2020 financial results conference call. This call will take place on Tuesday, May 5, 2020 at 10:00 a.m. ET.

  • Top Ranked Value Stocks to Buy for April 20th
    Zacks

    Top Ranked Value Stocks to Buy for April 20th

    Top Ranked Value Stocks to Buy for April 20th

  • Billionaire Steven Cohen Snaps up These 2 Stocks as Markets Rebound
    TipRanks

    Billionaire Steven Cohen Snaps up These 2 Stocks as Markets Rebound

    Are the dark clouds that have been looming over Wall Street finally dissipating? The recent rally in stocks has generated hope among some investors that this is in fact the case. Driven by strong results from Gilead’s clinical trial evaluating remdesivir, its COVID-19 treatment, as well as President Trump’s plan to reopen the economy, all three of the major U.S. stock indexes wrapped up last week of trading in the green. This marked the first back-to-back weekly gains in over two months.Having said that, one investing guru is wary amid the market’s modest recovery. In a recent note to his staff, billionaire stock picker Steve Cohen argues that an economic recovery won’t necessarily be linear. He believes that while there are compelling names out there, the team needs to remain “disciplined”.Cohen’s investment firm, Point72 Asset Management, relies on a strategy that involves investments in the stock market as well as a more macro approach. This very strategy has cemented Cohen’s status as a highly respected investing powerhouse, with the guru earning $1.3 billion in 2019 thanks to a 14.9% gain in Point72′s main hedge fund.Bearing this in mind, we decided to take a page from Cohen’s playbook and look at two stocks the billionaire went in on recently. According to TipRanks’ database, both Buy-rated tickers sport substantial upside potential. Here’s the lowdown.Immunomedics (IMMU)Using cutting edge immunotherapeutics, Immunomedics is working to develop better treatments for cancer, autoimmune and other serious diseases. Even though it has already notched an 87% gain in the last month, some think that IMMU still has more fuel left in the tank.Judging by the new position acquired recently, Cohen appears to be one of the healthcare name’s fans. Disclosing the purchase on April 16, Point72 snapped up just under 11 million shares. As a result, the firm now boasts a 5.1% stake in IMMU.Several pieces of good news for the company inspired bullish sentiment from Guggenheim analyst Michael Schmidt. On April 6, IMMU revealed that it would be stopping its ASCENT Phase 3 study of sacituzumab in metastatic triple-negative breast cancer early on account of “compelling evidence of efficacy.” This is based on a unanimous recommendation made by the independent Data Safety Monitoring Committee (DSMC). According to management, “remarkable results” were witnessed across multiple endpoints. In addition, the data readout is still slated for mid-2020.Expounding on the implications of this development, Schmidt commented, “We think today's news significantly improves the outlook for IMMU, consistent with our bull-case scenario as investors had major concerns on the success probability of ASCENT and potential implications to sacituzumab's approvability. The news also read-though positively to the ongoing TROPiCS-02 Phase 3 trial in the large HR+/HER2- metastatic breast cancer indication.”On top of this, management announced that Harout Semerjian had been appointed President and CEO as well as a member of the Board. Semerjian brings plenty of experience to the table as he previously served as Ipsen’s Executive Vice President, Chief Commercial Officer, where he oversaw the global commercialization and portfolio strategy across oncology, neurosciences and rare diseases, and specialty operations in Europe and other international markets.Based on all of the above, it’s no wonder Schmidt stayed with the bulls. Along with his Buy rating, the five-star analyst bumped up the price target from $25 to $35. Should this target be met, a 74% twelve-month rise could be in store. (To watch Schmidt’s track record, click here)Looking at the consensus breakdown, 2 Buys, 1 Hold and 1 Sell add up to a Moderate Buy Street consensus. At $28, the average price target implies 39% upside potential. (See Immunomedics price targets and analyst ratings on TipRanks)BGC Partners, Inc. (BGCP)Inhabiting the financial sector, brokerage company BGC Partners takes pride in its world-class products delivered on a daily basis. While 2020 has seen the company shed a significant portion of its value, the weakness could present investors with an attractive entry point.This is the stance taken by Cohen. According to an April 16 disclosure, Point72 added 7,505,667 shares of BGCP, increasing its position by a whopping 93.6%. With the total holding now landing at 15,528,960 shares, the firm has 5% ownership of the company.Following an announcement made at the end of March, Piper Sandler analyst Richard Repetto also has high hopes for the brokerage name. BGCP stated that it expects to surpass its previous Q1 2020 guidance that was issued during the Q4 2019 earnings call. This guidance called for $540-$580 million in revenue and adjusted pre-tax income of $90-$106 million.Commenting on the news, Repetto noted, “Our proxy volumes for BGCP have increased from 24% (Credit proxies) to 53% (Equity and Other proxies) quarter-over-quarter in Q1 2020. Although these proxies are not perfectly correlated to BGCP's performance, we believe that the strong industry volumes likely provided a positive tailwind for the company's brokerage revenues.”That being said, the announcement wasn’t completely positive as BGCP will most likely reduce its quarterly dividend from $0.14 to $0.01. Elaborating on the decision, CEO Howard Lutnick said that the reduction wasn’t related to any liquidity issues, but was a “precautionary step to ensure the longevity and financial security of the company in unknown times.” Management also believes that its employees will understand the decision given the state of the market.Repetto is on the same page in that he thinks the company is doing what it needs to do to stay afloat. “We've witnessed BGCP Chairman and CEO Lutnick lead & operate his firm through several past crisis. We believe he has made the strength and survival of the firm his highest priority,” the five-star analyst explained.In line with his optimistic take, Repetto reiterated an Overweight call and $8 price target. This conveys his confidence in BGCP’s ability to soar 199% in the next year. (To watch Repetto’s track record, click here)Turning now to the rest of the Street, other analysts have been relatively quiet. Only one other review was published recently, with that analyst giving the stock a Hold rating. As a result, the analyst consensus is a Moderate Buy. Additionally, the $8 average price target matches Repetto’s. (See BGC Partners stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • 5 Stocks to Gain the Most With the Economy Set to Reopen
    Zacks

    5 Stocks to Gain the Most With the Economy Set to Reopen

    These five stocks are poised to grow with the guidelines laid out to reopen the economy, as coronavirus pandemic dissipates.